Nuwellis, Inc.

Nuwellis, Inc.

NNASDAQ:NUWE
4.48
USD
-0.42
(-8.57%)
-1,312.66EPS
1.75MMarket Cap
Mar 02Next Earn
Nuwellis, Inc.
NASDAQ:NUWE
(Nasdaq Stock Market)

Recent

price

4.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
561,181.41
- -
- -
893.94
4,402.99
819.44
1,289,000
1,776,500
1,249,500
5,511,000
7,441,000
3,960,500
8,543,000
738,666.67
26,484.85
3,776.26
1,044.86
Revenue per Share
-12,265,966.27
-16,196,000
-390,694.44
-329,666.67
-381,895.52
-369,208.33
-17,692,000
-12,486,000
-4,258,000
-22,623,000
-17,593,000
-9,814,500
-14,525,000
-1,885,583.33
-32,193.94
-7,998.63
-1,312.08
Basic EPS, GAAP
-10,803,979.01
-13,540,000
-367,805.56
-267,500
-343,208.96
-322,055.56
-16,409,000
-6,089,500
-3,689,500
-16,857,000
-16,870,000
-9,031,000
-15,271,000
-1,515,416.67
-29,245.45
-4,977.17
-1,469.86
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6,261,270.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12,357,000
249,166.67
19,781.82
490.19
-32.2
Book Value per Share
6,261,270.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12,357,000
249,166.67
19,781.82
490.19
-33.79
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
1
- -
- -
- -
- -
- -
1
4
5
6
7
8
9
9
9
8
9
Sales/Revenue/Turnover
-2,112.31
- -
- -
-38,764.41
-8,741.36
-43,996.61
-1,215.05
-305.69
-340.86
-328.54
-228.84
-246.51
-200.99
-198.89
-125.72
-134.29
-142.87
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-12
-16
-14
-22
-26
-27
-16
-13
-17
-18
-16
-20
-15
-20
-11
-18
-11
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-2,185.74
- -
- -
-36,877.97
-8,673.56
-45,055.93
-1,225.14
-376.64
-340.78
-328.69
-212.82
-246.86
-170.02
-227.99
-127.75
-211.86
-125.63
Profit Margin (%)
6
4
12
51
29
16
-1
16
5
1
15
25
18
5
6
2
4
Working Capital
- -
- -
- -
- -
- -
4
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
LT Debt
6
5
13
52
29
12
2
16
6
2
16
26
12
3
7
3
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-238.67
-298.34
-160.33
-67.28
-63.22
-128.46
-254.05
-277.54
-153.62
-570.86
-192.19
-92.89
-75.84
-294.87
-223.24
-382.8
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
3
3
2

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5
6
8
Cash, Cash Equivalents & STI
1
2
4
Accounts Receivable, Net
1
2
2
Inventories
2
2
2
Total Current Liabilities
3
4
4
Payables & Accruals
2
2
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
110.9%
-4.75%
-59.72%
Free Cash Flow
-4.28%
-4.66%
12.94%
Net Income, GAAP
1.43%
9.81%
56.93%
Sales/Revenue/Turnover
235.76%
2.26%
-5.38%
Total Cash Common Dividend
- -
- -
-99.26%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
2
2
2
9
2025
2
2
2
2
8
2026
2
2
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-270,642.86
-203,289.47
16,723.4
-4,448.48
-32,193.94
2025
-9,130.3
-7,502.69
176.65
-472.48
-7,998.63
2026
-689.08
-239.7
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Nuwellis, Inc. (Nasdaq: NUWE) develops, manufactures, and commercializes medical devices for ultrafiltration therapy to treat fluid overload in patients with heart failure, critical illness, and related conditions; its core products include the Aquadex SmartFlow and Aquadex FlexFlow systems, comprising consoles, disposable blood circuit sets, disposable catheters, and a new U.S.-launched 24-hour circuit alongside FDA-cleared dual-lumen extended-length catheters. The company, founded in 1999 and headquartered in Eden Prairie, Minnesota, sells directly to hospitals and clinics in the United States while distributing through independent partners in countries including Austria, Brazil, Germany, India, Israel, Italy, Singapore, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom; it targets critical care, cardiology, nephrology, and pediatric segments with approximately 47 pediatric centers adopting Aquadex therapy. Recent developments encompass a May 2024 purchase agreement with a top-25 U.S. integrated delivery network for Aquadex deployment across 50 hospitals, a strategic manufacturing transition to KDI Precision Manufacturing, a $5 million capital raise in Q2 2025, expanded CMS reimbursement enabling first hospital-based outpatient therapies, new U.S. patents for fluid bag designs and blood return line clamps, participation in a $3 million NIH grant via partner Koronis Biomedical for the Vivian pediatric CRRT system, and an August 2025 non-binding letter of intent to acquire Rendiatech Ltd. for its FDA-cleared Clarity RMS real-time urine flow and acute kidney injury monitoring technologies, anticipated to close in Q4 2025.

Company News

  • Nuwellis, Inc. (NUWE) Q3 2026 Earnings Call Transcript

  • Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss

  • Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children

  • Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and Above

  • Nuwellis to Report Third Quarter 2026 Financial Results on November 12

  • Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

  • Nuwellis, Inc. (NASDAQ:NUWE) Shares Shorted: Short Interest Up 339.6% in September

  • Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

  • Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

  • Nuwellis, Inc. (NASDAQ:NUWE) Sees Significant Decline in Short Interest

  • Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

  • Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

  • Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins

  • Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

  • Nuwellis, Inc. (NUWE) Q2 2026 Earnings Call Prepared Remarks Transcript

  • Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

  • Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer

  • Nuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care Applications

  • Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  • Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy